Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions

Inducible, microsomal prostaglandin E synthase 1 (mPGES-1), the terminal enzyme in the prostaglandin (PG) biosynthetic pathway, constitutes a promising therapeutic target for the development of new anti-inflammatory drugs. To elucidate structure–function relationships and to enable structure-based design, an mPGES-1 homology model was developed using the three-dimensional structure of the closest homologue of the MAPEG family (Membrane Associated Proteins in Eicosanoid and Glutathione metabolism), mGST-1. The ensuing model of mPGES-1 is a homo-trimer, with each monomer consisting of four membrane-spanning segments. Extensive structure refinement revealed an inter-monomer salt bridge (K26-E77) as well as inter-helical interactions within each monomer, including polar hydrogen bonds (e.g. T78-R110-T129) and hydrophobic π-stacking (F82-F103-F106), all contributing to the overall stability of the homo-trimer of mPGES-1. Catalytic co-factor glutathione (GSH) was docked into the mPGES-1 model by flexible optimization of both the ligand and the protein conformations, starting from the initial location ascertained from the mGST-1 structure. Possible binding site for the substrate, prostaglandin H2 (PGH2), was identified by systematically probing the refined molecular structure of mPGES-1. A binding model was generated by induced fit docking of PGH2 in the presence of GSH. The homology model prescribes three potential inhibitor binding sites per mPGES-1 trimer. This was further confirmed experimentally by equilibrium dialysis study which generated a binding stoichiometric ratio of approximately three inhibitor molecules to three mPGES-1 monomers. The structural model that we have derived could serve as a useful tool for structure-guided design of inhibitors for this emergently important therapeutic target.

[1]  Makoto Murakami,et al.  Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. , 2005, Journal of biochemistry and molecular biology.

[2]  Ying Yu,et al.  Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. , 2006, The Journal of clinical investigation.

[3]  Makoto Murakami,et al.  Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.

[4]  S. Miyamoto,et al.  Membrane-associated prostaglandin E synthase-1 is upregulated by proinflammatory cytokines in chondrocytes from patients with osteoarthritis , 2004, Arthritis research & therapy.

[5]  Makoto Murakami,et al.  Molecular Identification of Cytosolic Prostaglandin E2 Synthase That Is Functionally Coupled with Cyclooxygenase-1 in Immediate Prostaglandin E2Biosynthesis* , 2000, The Journal of Biological Chemistry.

[6]  Seiji Ito,et al.  Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. , 2002, Biochemical and biophysical research communications.

[7]  N. Méthot,et al.  Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. , 2005, Bioorganic & medicinal chemistry letters.

[8]  Masashi Miyano,et al.  Crystal structure of a human membrane protein involved in cysteinyl leukotriene biosynthesis , 2007, Nature.

[9]  Sanjay M Jachak.  PGE synthase inhibitors as an alternative to COX-2 inhibitors. , 2007, Current opinion in investigational drugs.

[10]  D. Toft,et al.  Crystal Structure and Activity of Human p23, a Heat Shock Protein 90 Co-chaperone* , 2000, The Journal of Biological Chemistry.

[11]  Chang-Guo Zhan,et al.  Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. , 2006, Bioorganic & medicinal chemistry.

[12]  N. Méthot,et al.  Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[13]  Makoto Murakami,et al.  Reduced Pain Hypersensitivity and Inflammation in Mice Lacking Microsomal Prostaglandin E Synthase-1* , 2004, Journal of Biological Chemistry.

[14]  Per-Johan Jakobsson,et al.  Human microsomal prostaglandin E synthase 1: a member of the MAPEG protein superfamily. , 2005, Methods in enzymology.

[15]  Jesper Z. Haeggström,et al.  Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase , 2007, Nature.

[16]  M. Murakami,et al.  Segregated coupling of phospholipases A2, cyclooxygenases, and terminal prostanoid synthases in different phases of prostanoid biosynthesis in rat peritoneal macrophages. , 1998, Journal of immunology.

[17]  K. Seibert,et al.  Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo , 1996, The Journal of experimental medicine.

[18]  H. Fahmi,et al.  mPGES-1 as a novel target for arthritis , 2004, Current opinion in rheumatology.

[19]  Ralf Morgenstern,et al.  Structural basis for detoxification and oxidative stress protection in membranes. , 2006, Journal of molecular biology.

[20]  Makoto Murakami,et al.  Cellular Prostaglandin E2 Production by Membrane-bound Prostaglandin E Synthase-2 via Both Cyclooxygenases-1 and -2* , 2003, Journal of Biological Chemistry.

[21]  Makoto Murakami,et al.  Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. , 2004, Progress in lipid research.

[22]  Ralf Morgenstern,et al.  Human Microsomal Prostaglandin E Synthase-1 , 2003, Journal of Biological Chemistry.

[23]  D. Riendeau,et al.  Cloning, Expression, and Up-regulation of Inducible Rat Prostaglandin E Synthase during Lipopolysaccharide-induced Pyresis and Adjuvant-induced Arthritis* , 2001, The Journal of Biological Chemistry.

[24]  Chang-Guo Zhan,et al.  Human Microsomal Prostaglandin E Synthase-1 (mPGES-1) Binding with Inhibitors and the Quantitative Structure-Activity Correlation , 2008, J. Chem. Inf. Model..

[25]  Shizuo Akira,et al.  Lipopolysaccharide-Dependent Prostaglandin E2 Production Is Regulated by the Glutathione-Dependent Prostaglandin E2 Synthase Gene Induced by the Toll-Like Receptor 4/MyD88/NF-IL6 Pathway1 , 2002, The Journal of Immunology.

[26]  Shizuo Akira,et al.  Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Persson,et al.  Common structural features of mapeg—a widespread superfamily of membrane associated proteins with highly divergent functions in eicosanoid and glutathione metabolism , 2008, Protein science : a publication of the Protein Society.

[28]  Ralf Morgenstern,et al.  Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target , 2007, Pharmacological Reviews.

[29]  K Watanabe,et al.  Two types of microsomal prostaglandin E synthase: glutathione-dependent and -independent prostaglandin E synthases. , 1997, Biochemical and biophysical research communications.

[30]  J. Thompson,et al.  The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.

[31]  Tetsuya Abe,et al.  Membrane-associated prostaglandin E synthase-1 is required for neuropathic pain , 2004, Neuroreport.

[32]  Xuefeng Fan,et al.  Genomic structure and genitourinary expression of mouse cytosolic prostaglandin E2 synthase gene , 2003 .

[33]  T. Grosser,et al.  Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.

[34]  Chisato Miyaura,et al.  Membrane-Bound Prostaglandin E Synthase-1-Mediated Prostaglandin E2 Production by Osteoblast Plays a Critical Role in Lipopolysaccharide-Induced Bone Loss Associated with Inflammation , 2006, The Journal of Immunology.

[35]  Norio Matsuki,et al.  Microglia‐specific expression of microsomal prostaglandin E2 synthase‐1 contributes to lipopolysaccharide‐induced prostaglandin E2 production , 2005, Journal of neurochemistry.

[36]  Ralf Morgenstern,et al.  Bioinformatic and enzymatic characterization of the MAPEG superfamily , 2005, The FEBS journal.

[37]  Atsushi Ichikawa,et al.  Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3 , 1998, Nature.

[38]  Taro Yamada,et al.  PGH2 degradation pathway catalyzed by GSH-heme complex bound microsomal prostaglandin E2 synthase type 2: the first example of a dual-function enzyme. , 2007, Biochemistry.

[39]  B. Samuelsson,et al.  Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Jilly F. Evans,et al.  Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein , 2007, Science.

[41]  Chang-Guo Zhan,et al.  Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation. , 2008, The journal of physical chemistry. B.

[42]  P. Isakson,et al.  Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. , 1995, Journal of immunology.

[43]  Y. Ohmiya,et al.  Crystal structure and possible catalytic mechanism of microsomal prostaglandin E synthase type 2 (mPGES-2). , 2005, Journal of molecular biology.

[44]  Makoto Murakami,et al.  Prostaglandin E synthase: a novel drug target for inflammation and cancer. , 2006, Current pharmaceutical design.